Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Circulating Levels Are Related to LDL Coronary Artery Disease

Authors

  • Thoalffakar A. Alhamed Ph.D. Student in Department of Biology, College of Education for Pure Sciences, University of Karbala, Iraq
  • Liqaa H. Saqban Dr. Prof in Department of Biology, College of Education for Pure Sciences, University of Karbala, Iraq
  • Arshad Noori Ghani Al-Dujaily Dr. Department of Biology, College of Science, Kufa University, Iraq

Keywords:

proprotein convertase subtilisin/kexin type-9 (PCSK9) ,Low-density lipoprotein receptors (LDL-R) . coronary artery disease.

Abstract

Background: Low-density lipoprotein receptors (LDL-R) in hepatocytes are degraded by the enzyme proprotein convertase subtilisin/kexin type-9 (PCSK9). A brand-new target for lipid-lowering treatment is PCSK9 inhibition. Three subsets of monocytes, which play a critical role in the pathophysiology of atherosclerosis, are known

Objectives: The aim of this study was to examine whether circulating levels of PCSK9 are associated with LDL liped subsets.

Materials and Methods: We included 70 patients with coronary artery disease. PCSK9 levels were mea- sured and LDL liped and 30 control health

Results: Eighty percent of the patients were men, with a mean age between 40 and 70. Patients increese displayed greater PCSK9-levels compared to the 30 male control group. PCSK9 levels in the blood were associated with CM treatment in patients, whereas NCM had the opposite effect. Patients whose levels of PCSK9 were greater than the median displayed a significantly higher.

Downloads

Published

2023-12-16

How to Cite

Alhamed, T. A., Saqban, L. H., & Al-Dujaily, A. N. G. (2023). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Circulating Levels Are Related to LDL Coronary Artery Disease. World of Science: Journal on Modern Research Methodologies, 2(12), 113–124. Retrieved from https://univerpubl.com/index.php/woscience/article/view/2889